Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial

Schadendorf, D. and Hassel, J. C. and Fluck, M. and Eigentler, T. and Loquai, C. and Haferkamp, S. and Gutzmer, R. and Meier, F. and Mohr, P. and Hauschild, A. and Menzer, C. and Kiecker, F. and Dippel, E. and Simon, J-C. and Conrad, B. and Garbe, C. and Körner, S. and Becker, J. C. and Zimmer, L. and Livingstone, E. (2022) Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial. ANNALS OF ONCOLOGY, 33 (Suppl7). S900. ISSN 0923-7534, 1569-8041

Full text not available from this repository.

Item Type:	Article
Subjects:	600 Technology > 610 Medical sciences Medicine
Divisions:	Medicine > Lehrstuhl für Dermatologie und Venerologie
Depositing User:	Petra Gürster
Date Deposited:	04 Jul 2024 10:07
Last Modified:	04 Jul 2024 10:07
URI:	https://pred.uni-regensburg.de/id/eprint/58554

Actions (login required)

View Item